<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01536158</url>
  </required_header>
  <id_info>
    <org_study_id>ZTB150212</org_study_id>
    <nct_id>NCT01536158</nct_id>
  </id_info>
  <brief_title>Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled Trial</brief_title>
  <official_title>Oral Paracetamol Versus Oral Ibuprofen Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zekai Tahir Burak Women's Health Research and Education Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zekai Tahir Burak Women's Health Research and Education Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether oral paracetamol or ibuprofen has a better
      or same efficacy and tolerance in closure of patent ductus arteriosus in preterm infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine whether oral paracetamol or ibuprofen has a better or same efficacy and
      tolerance in closure of patent ductus arteriosus in preterm infants.

      Eighty preterm infants with patent ductus arteriosus will be enrolled in this
      prospective-randomized study. Patients will receive oral ibuprofen at an initial dose of 10
      mg/kg, followed by 5 mg/kg at 24 and 48 h or oral paracetamol 15 mg/kg per dose every 6
      hours.

      One of the following echocardiographic criteria of a duct size &gt;1.5 mm, a left
      atrium-to-aorta ratio &gt;1.5, left-to-right shunting of blood, end diastolic reversal of blood
      flow in the aorta, or poor cardiac function in addition signs of patent ductus arteriosis
      determined the need of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy and Safety of Oral Paracetamol Versus Oral Ibuprofen</measure>
    <time_frame>Until discharge</time_frame>
    <description>To compare the closure rate of patent ductus arteriosus after oral paracetamol or oral ibuprofen treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long term effects of oral paracetamol versus oral ibuprofen treatment in preterm infants</measure>
    <time_frame>corrected 36 weeks or until discharge</time_frame>
    <description>Long term effects such as ROP, BPD,IVH, duration of respiratory support and hospitalization are going to be evaluated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Patent Ductus Arteriosus</condition>
  <arm_group>
    <arm_group_label>Oral paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral paracetamol</intervention_name>
    <description>Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days.</description>
    <arm_group_label>Oral paracetamol</arm_group_label>
    <other_name>Calpol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral ibuprofen</intervention_name>
    <description>Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.</description>
    <arm_group_label>Oral ibuprofen</arm_group_label>
    <other_name>Pedifen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Birth weight below 1250 gram

          -  Diagnosed patent ductus arteriosus by Echocardiographic examination

        Exclusion Criteria:

          -  Accompanied other congenital cardiac anomalies

          -  Urine output of less than 1 ml/kg/h during the preceding 8 h,

          -  Serum creatinine level &gt;1.6 mg/dl,

          -  Platelet count &lt;60,000/mm3,

          -  Liver failure,

          -  Hyperbilirubinemia requiring exchange transfusion

          -  Severe intracranial bleeding (Grade III - IV)

          -  Intestinal abnormality and necrotising enterocolitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>10 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet Yekta Oncel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zekai Tahir Burak Women's Health Research and Education Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zekai Tahir Burak Maternity Teaching Hospital, Division of Neonatology</name>
      <address>
        <city>Ankara</city>
        <zip>06110</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0015687271&amp;QV1=IBUPROFEN</url>
    <description>Ibuprofen</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0000103902&amp;QV1=PARACETAMOL</url>
    <description>Paracetamol</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2012</study_first_submitted>
  <study_first_submitted_qc>February 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2012</study_first_posted>
  <last_update_submitted>December 24, 2012</last_update_submitted>
  <last_update_submitted_qc>December 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zekai Tahir Burak Women's Health Research and Education Hospital</investigator_affiliation>
    <investigator_full_name>Mehmet Yekta</investigator_full_name>
    <investigator_title>Zekai Tahir Burak Maternity and Teaching Hospital</investigator_title>
  </responsible_party>
  <keyword>Patent Ductus Arteriosus</keyword>
  <keyword>Paracetamol</keyword>
  <keyword>Ibuprofen</keyword>
  <keyword>Preterm infant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

